Vandetanib

Generic Name: Vandetanib

Brand Names: Caprelsa

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄BrFN_₄O_₂

CAS Number: 443913-73-3

Unique Ingredient Identifier: YO460OQ37K

Background: Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Indication: Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Associated Conditions: Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer

Clinical Trials

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

Phase 1

Terminated

Conditions: Neuroblastoma

Interventions: Drug: ZD6474
Drug: Retinoic Acid

First Posted Date: 2007-09-21

Last Posted Date: 2011-12-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00533169

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Phase 1

Completed

Conditions: Medullary Thyroid Carcinoma
Multiple Endocrine Neoplasia Type 2A
Multiple Endocrine Neoplasia Type 2B

Interventions: Drug: Vandetanib

First Posted Date: 2007-08-09

Last Posted Date: 2020-12-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00514046

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Vandetanib
Drug: Best Supportive Care

First Posted Date: 2007-07-27

Last Posted Date: 2016-10-10

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 67

Registration Number: NCT00508001

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

Phase I Chinese PK

Phase 1

Completed

Conditions: Advanced Solid, Malignant Tumors

Interventions: Drug: Vandetanib
Drug: Vandetanib 300 mg

First Posted Date: 2007-07-19

Last Posted Date: 2016-08-31

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 36

Registration Number: NCT00503711

Locations: 🇨🇳
Research Site, Guangzhou, China

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal
Cancer

Interventions: Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Drug: Vandetanib

First Posted Date: 2007-07-12

Last Posted Date: 2018-01-25

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 109

Registration Number: NCT00500292

Locations: 🇨🇳
Research Site, Tao-Yuan, Taiwan

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Vandetanib
Drug: Cyclophosphamide
Drug: Methotrexate

First Posted Date: 2007-07-04

Last Posted Date: 2013-11-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00496665

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

E3 Breast Cancer Taxotere Combination

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Vandetanib (ZD6474)
Drug: Docetaxel

First Posted Date: 2007-06-29

Last Posted Date: 2016-09-30

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 64

Registration Number: NCT00494481

Locations: 🇪🇸
Research SIte, Lérida, Spain
🇨🇳
Research Site, Taipei, Taiwan

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Vandetanib
Drug: Anastrozole

First Posted Date: 2007-06-04

Last Posted Date: 2017-02-07

Lead Sponsor: Stanford University

Target Recruit Count: 1

Registration Number: NCT00481845

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: vandetanib

First Posted Date: 2007-05-10

Last Posted Date: 2012-10-15

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 35

Registration Number: NCT00472017

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Docetaxel
Drug: ZD6474

First Posted Date: 2007-04-11

Last Posted Date: 2013-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00459043

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Loyola University Medical Center/Cardinal Bernadin Cancer Center, Maywood, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy